Bharat Biotech to begin Phase-1 trials of its intranasal vaccine for Covid-19 in Feb-March

Buoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI)for its Covid-19 vaccine Covaxin, Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.